Source comparison
KPV Dosage Comparison: Clinical Research Protocols
Gastrointestinal (IBD, colitis) 500 mcg SC Twice daily Intestinal mucosa, epithelial cells 40–60% reduction in colonic inflammation scores; histological improvement in crypt architecture and immune infiltration (World Journal of Gastroenterology, 2015) Twice-d
This comparison does not assign a generated winner or score.
- Gastrointestinal (IBD, colitis)
- 500 mcg SC
- Twice daily
- Intestinal mucosa, epithelial cells
- 40–60% reduction in colonic inflammation scores; histological improvement in crypt architecture and immune infiltration (World Journal of Gastroenterology, 2015)
- Twice-daily dosing is critical for sustained NF-κB suppression in active GI inflammation. Single daily dosing produced weaker effects
- Dermatological (contact dermatitis, UV damage)
- 250 mcg SC
- Once daily
- Localised skin tissue
- 30–45% reduction in erythema, edema, and cytokine expression in UV-irradiated skin (Peptides, 2018)
- Lower dose sufficient due to localised target and high peptide concentration achieved via near-site subcutaneous injection
- Systemic (chronic low-grade inflammation)
- 250–500 mcg SC
- Systemic circulation
- Dose-dependent reduction in CRP, IL-6, TNF-α; titration from 250 mcg upward based on biomarker response
- Start at 250 mcg and increase only if baseline inflammation is severe. Higher doses don't improve outcomes once receptor saturation is achieved
- Acute inflammation (post-injury, exercise-induced)
- Once daily for 5–7 days
- Localised or systemic
- Reduction in post-exercise IL-6 spike and muscle soreness duration in preliminary research
- Short-term protocols use lower doses; KPV's receptor-mediated mechanism doesn't require high doses for acute inflammatory spikes